Background. To determine the impact of variant pancreatic arterial anatomy and overlap in regional perfusion on the interpretation of selective arterial calcium stimulation (SACST) with hepatic venous sampling for preoperative localization of occult insulinoma.
concentrations of calcium differentially stimulate b-cells within insulinomas to secrete insulin in contrast with normal pancreatic b-cells. [3] [4] [5] The original SACSTcriteria described by Doppman required a $2-fold increase in hepatic venous insulin concentration over baseline for positive localization. According to Doppman, a positive response after injection of the superior mesenteric artery (SMA) localized the insulinoma to the inferior pancreatic head and uncinate process, a positive result after gastroduodenal artery (GDA) injection localized the insulinoma to the superior pancreatic head or neck and a positive response after splenic artery (SPA) injection localized the insulinoma to the pancreatic body and tail. 1 The localization information helps to guide the endocrine surgeon as to the type and extent of operative resection. 6 Previous studies have identified significant variation in pancreatic arterial anatomy. [7] [8] [9] [10] [11] Moreover, a recent study evaluating the vascular supply to regions of the pancreas using CT during arteriography revealed significant variation and overlap in pancreatic regional perfusion by the major pancreatic arteries. 12 Doppman's original criteria for interpreting the biochemical results of SACST do not take into account the impact of variant pancreatic arterial anatomy and regional perfusion for localization of occult insulinoma. Therefore, the aim of the present study was to evaluate the impact of variant pancreatic arterial anatomy and overlap in regional perfusion on the interpretation of SACST for preoperative localization of occult insulinoma.
MATERIALS AND METHODS
After approval by the institutional review board, we conducted a Health Insurance Portability and Accountability Act-compliant, retrospective review using the comprehensive electronic medical record system of all patients with surgically confirmed occult insulinoma who underwent preoperative SACST in the period from January 1, 1996, to March 5, 2014 . This time period was selected based on the introduction of SACST into clinical practice at our institution. Patients who did not give approval for the use of their medical record for research purposes and patients with metastatic insulinoma were excluded. Demographic, clinical, imaging, surgery, and pathology data were collected.
Patient selection for SACST. The approach to management of insulinoma at our institution has been described previously. 6 In all patients, an initial effort to localize insulinoma utilizes noninvasive modalities including transabdominal ultrasound and/or triple-phase CT of the pancreas.
During the study period, 46 of 229 patients (20.0%) evaluated at our institution for insulinoma confined to the pancreas underwent SACST. SACST was performed owing to negative noninvasive imaging, negative endoscopic ultrasonography (EUS), patient and/or outside endocrinology referral specifically for SACST or inconclusive preoperative localization, including (1) atypical or equivocal lesion morphology or enhancement on noninvasive imaging modalities, (2) multiple endocrine neoplasia type (MEN)-1 patients with multiple (>1) pancreatic lesions on imaging and need to determine which lesion(s) may be functional, (3) patients with postprandial symptoms and need to confirm that lesion(s) observed by cross-sectional imaging were indeed functional, and (4) patients with prior failed pancreatic exploration elsewhere and need to confirm that lesion(s) observed by cross-sectional imaging were functional.
SACST with hepatic venous sampling. SACST was performed as an outpatient procedure as previously described. 13 Under conscious sedation, 5-Fr catheters were inserted into both the right femoral artery and vein using the Seldinger technique. Under fluoroscopic guidance, the venous catheter was positioned in the right hepatic vein for blood sampling. Standard pancreatic arteriography was performed after selective catheterization of the celiac artery, GDA, SPA, and SMA as well as the dorsal pancreatic artery (DPA) if necessary. After diagnostic arteriography, calcium gluconate (0.025 mEq Ca 2+ /kg) diluted to a 5-mL bolus was rapidly injected into the GDA, SPA, and SMA as well as the DPA in select cases. Five milliliters of blood were obtained from the right hepatic vein before the injection (baseline; t = 0) and 20, 40, and 60 seconds after calcium injection. Five minutes were allowed between arterial stimulations. Five milliliters of arterial blood were also obtained before injection of calcium gluconate from each systemic artery. Insulin concentrations were determined by electrochemiluminescent immunoassay (Roche Diagnostic Corp., Indianapolis, IN) by the clinical laboratory.
SACST review and interpretation. Blinded review of SACST occurred in a step-wise manner. First, localization of the insulinoma was initially predicted by an independent observer (S.M.T.) blinded to any patient information based on the biochemical results from SACST alone using Doppman's criteria---doubling of the hepatic insulin concentration after SMA stimulation localized the insulinoma to the uncinate process and inferior head, after GDA stimulation to the superior head and neck and after SPA stimulation to the body and tail. 1, 13, 14 Next, the arteriograms were reviewed by an experienced interventional radiologist (J.C.A.) blinded to the biochemical results to determine (1) the pancreatic arterial anatomy including the celiac trunk and its major branches---GDA, SPA, DPA, common hepatic artery, proper hepatic artery, left gastric artery, and right and left hepatic arteries---and the SMA, (2) the region(s) of the pancreas perfused by each vessel using surgical pancreatic anatomy criteria, and (3) evidence of a tumor stain. 15, 16 The anatomic, perfusion, and biochemical data were then combined to independently predict insulinoma localization. Finally, both predictions were compared with the surgical and pathology findings. Localization by arteriography alone was defined as evidence of a tumor stain on the arteriogram independent of the biochemical results. Localization by anatomic and regional perfusion was defined as an interpretation of the biochemical results in the context of the anatomic perfusion of the pancreas by each vessel.
Data management and statistical methods. Study data were collected and managed using REDCap electronic data capture tools. 17 Data were subsequently analyzed using JMP 8.0 (Raleigh, NC). Descriptive statistics were generated.
RESULTS
Patient data. Fifty patients with biochemical confirmation of insulinoma requiring blood glucose of <50 mg/dL, concomitant insulin level of >3-6 mIU/mL, depending on type of assay to verify measurable insulin was present during symptomatic hypoglycemia, increased C-peptide level ($1.2 ng/mL), negative sulfonylurea screen, negative or inconclusive noninvasive preoperative localization studies, and surgically confirmed occult insulinoma were identified who underwent SACST during from January 1, 1996, to March 5, 2014. 6 Four patients were excluded because they did not give consent for the use of their medical record for research purposes and 4 patients were excluded owing to a final diagnosis of metastatic insulinoma. The final review included 42 patients. Demographic, clinical, surgical and pathologic data are summarized in Tables I and II . There were no postoperative deaths and no recurrence of hypoglycemic symptoms.
SACST. Forty-two patients underwent 44 SACST procedures. The test was repeated in 2 patients owing to initial uninterpretable data (see Repeat SACST). There were no immediate, short-term, or long-term complications owing to the SACST procedure. In particular, there were no hypoglycemic episodes after calcium injection during SACST.
Biochemical data: Hepatic venous insulin concentration. The median maximal increase in insulin concentration over baseline from the dominant artery was 15.9-fold (range, 2.1 to 141.7-fold). The percent biochemically positive arterial distributions by vessel are summarized in Table III . Pancreatic arterial anatomy. The celiac trunk and superior mesenteric arterial anatomy were aberrant in 16 patients (38.1%) and 15 patients (35.7%), respectively (Table IV) Portal venous anatomy. Forty-one patients (97.6%) had patent superior mesenteric vein, splenic vein, and portal vein. One patient had a partially occluded splenic vein near the splenic hilum with numerous varices draining into left renal vein causing a portosystemic shunt (see Repeat SACST; Fig 3) .
Pancreatic regional perfusion by vessel. Significant variation and overlap in regional pancreatic perfusion by the major pancreatic arteries was observed, particularly for the SMA (Table V) . For example, the SMA perfused the uncinate process alone in 31.0% of patients but the entire pancreas in 19.0% of patients.
SACST localization. Diagnostic arteriography alone had a sensitivity of 54.8% for insulinoma localization. Incorporating pancreatic arterial anatomic and regional perfusion data with biochemical data improved sensitivity of localization over biochemical data alone from 73.8 to 88.1%. Diagnostic arteriography in combination with biochemical, pancreatic arterial anatomy, and regional perfusion data improved sensitivity of localization to 92.9%. There were 2 patients in whom the biochemical data from SACST were positive but nonlocalizing and 1 patient in whom the biochemical results were negative and failed to demonstrate a 2-fold increase in hepatic venous insulin concentration in any arterial distribution.
Repeat SACST. Two of 44 SACST procedures produced initial uninterpretable biochemical data. In the first patient, hepatic venous insulin levels were unchanged after calcium stimulation in all arteries. Diagnostic arteriography identified a partial splenic vein occlusion in the splenic hilum with drainage into the left renal vein (Fig 3, A) . Systemic arterial insulin levels were higher than the hepatic venous insulin levels suggesting portosystemic shunting through the splenic hilar collaterals. Repeat SPA stimulation with sampling from the left renal vein identified an 11-to 18-fold increase in insulin levels, localizing the insulinoma to the pancreatic tail, later confirmed at surgical exploration (Fig 3, B and C) . In the second patient, the baseline systemic arterial insulin value before the SMA injection and the hepatic venous insulin concentration for the SMA stimulation at time 0 (SMA was the first artery stimulated) were increased relative to other samples. Because we were unable to explain these data, the study was repeated. The second study was performed with stimulation of the GDA and SPA, and followed by stimulation in the SMA. This repeat study was positive only with the SMA stimulation, localizing the insulinoma to the uncinate process, a finding confirmed at surgery.
Comparison of SACST with inconclusive preoperative localization studies. Of 42 patients, 19 (45.2%) had inconclusive noninvasive preoperative localization studies and 23 of the 42 (54.8%) had negative noninvasive localization studies. SACST confirmed the preoperative localization study and correctly localized the insulinoma in 16 of 19 patients (78.9%) with initial inconclusive noninvasive localization. In 3 of 19 patients, SACST correctly localized the insulinoma, whereas the initial noninvasive localization studies gave a false-positive localization. In a final patient with MEN-1, SACST was positive but nonlocalizing for the multiple lesions seen on cross-sectional imaging.
DISCUSSION
Adult hypoglycemic disorders resulting from endogenous hyperinsulinism may be complex to evaluate and manage. 6 Insulinoma is the most common cause of adult endogenous hyperinsulinemic hypoglycemia, but is relatively uncommon with an incidence of approximately 4 cases per million per year. 18 These tumors are most often small, solitary, benign, and intrapancreatic with an even distribution throughout the gland. 18, 19 Although most often sporadic (90%), the tumors may be part of the MEN-1 syndrome resulting in multiple islet cell tumors (<10%). 18, 20, 21 Pancreatic resection or enucleation is the treatment of choice for insulinoma with cure rates of 98% at experienced centers. 19 Preoperative anatomic localization helps the surgeon to plan the type and extent of surgery and may influence a decision to undertake a laparoscopic versus an open operative approach. Almost as important is that prior localization facilitates patient counseling during the process of obtaining informed consent. Although intraoperative ultrasonography combined with intraoperative palpation were highly successful in the present cohort of patients with occult insulinoma, it is known that blind pancreatic exploration may fail 2% of the time. 22, 23 As such, the practice at our institution is to localize preoperatively insulinomas to obviate the need for blind pancreatic exploration. Preoperative localization or regionalization is achieved with a combination of noninvasive and invasive imaging. Despite advances in noninvasive cross-sectional imaging techniques such as ultrasonography, CT, and MRI, insulinomas <2.0 cm remain difficult to localize. 20 In a large series, approximately one-quarter to one-third of insulinomas were not localized with noninvasive imaging and required invasive techniques for preoperative localization. 6 During this study period, 70-80% of patients had successful preoperative localization with noninvasive imaging; 20% of patients underwent SACST (46 of 229 patients evaluated at our institution with insulinoma confined to the pancreas). 6 Therefore, SACST is performed in a relatively small proportion of insulinoma patients. The average insulinoma size was 1.6 cm with 50% of the insulinomas <1.3 cm, thereby supporting previous studies that demonstrate that small insulinomas are difficult to detect noninvasively. An alternative, invasive modality to SACST for the localization of occult insulinoma is EUS. EUS combined with FNA can provide anatomic, pathologic, and potentially biochemical data with an insulin assay. 24 However, such data depend on the identification of a lesion that can be biopsied by EUS. In general, if a solitary lesion observed on EUS has a typical morphologic appearance for an islet cell tumor, we do not advocate for biopsy because the information provided rarely changes management, exposes patients to the risk of biopsy, and may delay pancreatic exploration for possible enucleation to ensure inflammation is minimized. Although precise preoperative localization is not always possible, functional data from SACST can regionalize the insulinoma to the left or right of the superior mesenteric vein and help to guide directed operative exploration with intraoperative ultrasonography.
Previous studies on SACST have reported sensitivities ranging from 40 to 100% in localizing occult insulinoma. 25, 26 However, these studies have not considered the impact of variant pancreatic arterial anatomy and regional perfusion on the interpretation of SACST. In the present study, the regions of the pancreas perfused by the SMA and GDA differed to varying degrees from that which was assumed by Doppman's criteria in 69 and 74%, of patients respectively. Clinically significant variations included replacement of DPA to SMA in 9 patients (21.4%; Fig 1, A and B) and celiac stenosis in 2 patients (4.8%). These findings have several implications. First, in the presence of DPA replaced to SMA, the SMA may perfuse the entire pancreas (Fig 1) . In the present series, the SMA perfused the entire pancreas in 19.0% of patients and the pancreatic uncinate process and head alone in <43% of patients (Table V) . Based on Doppman criteria, positivity in the SMA would localize an insulinoma in the uncinate process and inferior head, thereby supporting operative exploration to the right of the SMA and an enucleation or pancreatioduodenectomy for definitive treatment. However, blind interpretation may result in a false-positive localization, thereby supporting an incorrect operative procedure.
Second, in the presence of celiac stenosis, calcium injection into the GDA does not provide localizing information (Fig 2, A) . In such cases, the SMA may supply the entire pancreas via retrograde flow through the GDA and common hepatic artery further complicating localization (Fig 2, A) . Third, anomalous venous drainage was rare, occurring in only 1 patient (2.4%) in the present series. However, the presence of splenic varices resulted in a portosystemic shunt from the splenic vein to the left renal vein and a false-negative initial localization after SPA injection (Fig 3) . Repeat SACST with injection of the SPA and subsequent venous BD, Pancreatic body; dBD, distal pancreatic body; DPA, dorsal pancreatic artery; GDA, gastroduodenal artery; HD, pancreatic head; iHD, inferior pancreatic head; NK, pancreatic neck; pBD, proximal pancreatic body; sHD, superior pancreatic head; SMA, superior mesenteric artery; SPA, splenic artery; T, pancreatic tail; UN, uncinate process.
sampling from the left renal vein localized the insulinoma to the distal pancreatic body and tail. As such, high baseline arterial but not venous insulin concentrations should raise concern for a portosystemic shunt. Given the variation in pancreatic perfusion by SMA, application of Cone-beam CT during the SMA arteriogram may help to better define the 3-dimensional perfusion of the pancreas by the SMA. 12, 27 Our predictions of regional pancreatic perfusion are based on planar arteriograms, which is a limitation. Previous studies have used CT obtained with arterial contrast injection to define regional pancreatic perfusion. 16, 27 With the newly available cone-beam CT technology available in many angiography suites, this may be added to the SACST procedure. Moving forward, we plan to obtain cone-beam CT studies during the SMA injection for the baseline angiographic phase of the calcium stimulation, because this is the artery with the most clinically relevant anatomic variation.
Of the 42 patients with insulinoma confined to the pancreas, the biochemical results were positive ($2.0-fold) in 1 arterial distribution in 31 patients (73.8%), 2 distributions in 9 patients (21.4%), and 3 distributions in 2 patients (4.8%; Table III) . However, given the significant variation and overlap in regional perfusion distributions, the order of calcium gluconate injection may be relevant, particularly for SMA/GDA (n = 3) or SMA/SP (n = 3) when DPA replaced to SMA, because insulinomas contained within $2 overlapping perfusion distributions may theoretically be depleted of insulin on repeat stimulation resulting in falsely lower hepatic venous insulin concentrations. Additionally, although the majority of patients demonstrated positivity in only 1 arterial distribution, approximately 26% of patients had multiple arterial distributions that were positive: SMA/GDA (n = 3), GDA/SPA (n = 4), and SMA/SPA (n = 2), SMA/GDA/SPA (n = 1), and SMA/GDA/DP (n = 1). As such, interpretation and localization after positivity in $2 arterial distributions depends on the overlap of regional perfusion of the pancreas. For example, when positivity in both the SMA and SPA, if the SMA perfuses the entire pancreas and the SPA perfuses the body and tail, by deduction the lesion is likely in the pancreatic body or tail or at least to the left of the SMA. Alternatively, when positivity in the SMA but not the SPA---if the SMA perfuses the entire pancreas---by deduction, the lesion is likely to the right of the SMA in the pancreatic uncinate process or head (Fig 2) . Last, positivity in 2 nonoverlapping arterial distributions raises the concern for multiple insulinomas or nesidioblastosis, particularly in patients with a history of gastric bypass surgery or MEN-1 syndrome. 28 In the present study, arteriography alone demonstrated a sensitivity of 54.8%, similar to previous studies. 1, 13, [29] [30] [31] Application of Doppman's criteria for the interpretation of biochemical data alone demonstrated a sensitivity of 73.8%. However, incorporation of arteriography in combination with biochemical and pancreatic arterial and regional perfusion data improved sensitivity of localization to 92.9%. These data are similar to the largest published series with SACST from the NIH reporting a range of sensitivities from 84 to 94% over an 18-year period. 1, 2, 13, 14, 32 Taken together, these findings suggest that clinically significant variation in pancreatic arterial anatomy and overlap in regional perfusion impacts the interpretation of SACST and may result in localization errors.
Overall, there were 2 patients in whom the biochemical data from SACST were positive but nonlocalizing and 1 patient in whom the biochemical results were negative and failed to demonstrate a 2-fold increase in hepatic venous insulin concentration in any arterial distribution. In 1 patient, there was celiac stenosis and the DPA was replaced to the SMA resulting in perfusion of the entire pancreas by the SMA. The biochemical results from SACST demonstrated a 19.6-fold increase after injection of the SMA. Given the overlap in pancreatic regional perfusion, the results of SACST were positive but nonlocalizing. A subsequent EUS demonstrated a 3.5-cm hypoechoic mass in the pancreatic uncinate process. The patient underwent operative exploration with both intraoperative ultrasonography and palpation, which confirmed a 3.4-cm tumor in the pancreatic uncinate process with successful enucleation. In the second patient with a history of MEN-1 syndrome and gastric bypass surgery, the results of SACST were positive in the SMA (3.4-fold), GDA (5.6-fold), and SPA (8.5-fold) but nonlocalizing. The GDA and SMA supplied the pancreatic uncinate process, head, neck, and proximal body, and the SPA supplied the entire pancreatic body and tail. Given the concern for possible nesidioblastosis, the patient underwent a distal pancreatectomy, which demonstrated 0.2-and 0.8-cm islet cell tumors staining positive for insulin at the junction between the body and tail, but no evidence of nesidioblastosis. This case illustrates both the impact of overlapping pancreatic perfusion from multiple arterial distributions on the interpretation of SACST as well as the importance of considering both nesidioblastosis and insulinoma in patients undergoing SACST. The third patient in whom the biochemical results failed to demonstrate a 2-fold increase in hepatic venous insulin concentration in any arterial distribution had standard pancreatic arterial and venous anatomy. The patient did not have elevated baseline arterial or venous hepatic insulin levels. The negative results could not be explained by technical or laboratory error. The arteriogram did suggest a small hypervascular lesion in the pancreatic body. The patient underwent operative exploration with intraoperative ultrasonography, which identified a 0.7-cm tumor in the pancreatic body that was enucleated and stained positive for insulin.
In recent years, noninsulinoma pancreatogenous hypoglycemic syndrome (NIPHS) developing after Roux-en-Y gastric bypass surgery for medically complicated obesity has been associated with diffuse islet cell hyperplasia or nesidioblastosis. 28 NIPHS patients may be offered partial pancreatectomy to reduce their b islet cell mass and hypoglycemic symptoms. 33 Interestingly, there were 4 patients with surgically confirmed insulinoma in the present cohort who developed postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass surgery. As such, both nesidioblastosis and insulinoma need to be considered in the differential diagnosis in patients with a history of Roux-en-Y gastric bypass surgery undergoing SACST, as illustrated by the case of the patient with a history of gastric bypass surgery and a positive but nonlocalizing SACST. Service et al 18 previously reported a positive response in 1 (n = 1), 2 (n = 3), and 3 (n = 2) arterial distributions from SACST in 6 patients with surgically confirmed nesidioblastosis and a history of Roux-en-Y gastric bypass surgery, thereby suggesting that positivity in multiple arterial distributions may be suggestive of nesidioblastosis. However, in the present study, SACST demonstrated a positive response in 1 (n = 3) and 3 (n = 1; MEN-1) arterial distributions in patients with a history of gastric bypass surgery and 1 (n = 29), 2 (n = 11), and 3 (n = 2) arterial distributions in patients without a history of gastric bypass surgery. As such, positivity in multiple arterial distributions may not reliably differentiate between nesidioblastosis and insulinoma in patients with a history of Roux-en-Y gastric bypass surgery, particularly if there are nonoverlapping arterial distributions. In cases of multiple positive arterial distributions, the regional perfusion of each vessel needs to be reviewed carefully to identify mutually exclusive or overlapping arterial distributions while whole gland positivity is nonlocalizing.
In conclusion, clinically and angiographically significant variation in pancreatic arterial anatomy is common. The major pancreatic arteries may perfuse overlapping distributions, resulting in a $2-fold increase in hepatic venous insulin concentration after different arterial calcium stimulations yet only 1 insulinoma. As such, an insulin step-up in $2 arterial distributions should not be interpreted as exclusively nesidioblastosis or diffuse b-islet cell hyperplasia, but may include insulinoma. Although diagnostic arteriography alone has a sensitivity of just >50% for localizing insulinoma, combined with SACST it is highly sensitive (>90%) for localizing small, occult insulinoma. Table VI summarizes potential recommendations for problems encountered with the technique and interpretation of SACST.
Careful review of the pancreatic arterial anatomy and regional perfusion is critical for correct interpretation of the biochemical results of SACST and improves the sensitivity of localization for occult insulinoma. Importantly, the results of SACST should be interpreted by a multidisciplinary team with expertise in interventional radiology, endocrinology and endocrine surgery. Finally, both nesidioblastosis and insulinoma should be considered in the differential diagnosis of patients with a history of Roux-en-Y gastric bypass surgery and evidence of endogenous hyperinsulinism who undergo SACST.
